Nirmatrelvir exerts distinct antiviral potency against different human coronaviruses

Nirmatrelvir is the main component of Paxlovid, an oral antiviral drug approved for the treatment of COVID-19 caused by SARS-COV-2 infection. Nirmatrelvir targets the main protease (M(pro)), which is substantially conserved among different coronaviruses. Here, our molecular docking analysis indicate...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Jiajing, Wang, Yining, Solanki, Kundan, Atre, Rajat, Lavrijsen, Marla, Pan, Qiuwei, Baig, Mirza S., Li, Pengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925195/
https://www.ncbi.nlm.nih.gov/pubmed/36791846
http://dx.doi.org/10.1016/j.antiviral.2023.105555

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9925195/
https://www.ncbi.nlm.nih.gov/pubmed/36791846
http://dx.doi.org/10.1016/j.antiviral.2023.105555

Ejemplares similares